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Introduction. Estimate the efficacy of oral anticholeric vaccine 
Dukoral® in subjects travelling to high-risk areas for traveler’s 
diarrhoea and cholera.
Methods. The study involved subjects of both genders who planned 
to travel to high-risk areas for traveler’s diarrhoea and cholera. 
Immunization with oral anticholeric vaccine Dukoral® was offered 
to each one of them. Upon returning, all the participants in the study 
were asked to complete a self-administered questionnaire consisting 
of 40 close-ended questions mainly concerning: personal and health 
data, characteristics (length, destination, reason) of the travel, onset 
of gastrointestinal symptoms, data relating to the assumption of anti-
choleric vaccine and possible adverse reactions.
Results. 296 questionnaires have been collected. Mean age 
was 38.2 years (55.4% males and 44.6% females). Mean travel 
length was 22.2 days. Reasons for the travel: 66.8% tourism 
and 33.2% work-cooperation. Most frequent destination was 
Africa (48.1%), followed by Asia (32.1%) and Central South-
America (17.8%). 199 subjects (67.2%) properly executed vac-
cination with Dukoral®. The diarrhoea affected 14.1% of vacci-
nated subjects and 20.6% of non vaccinated ones. The following 
cohorts showed statistically significant differences in incidence 
of diarrhoea: < 35 years old age (13.7% vs. 27.1%), travel for 
work-cooperation (14.1% vs. 35%) and travel length > 28 days 
(12.1% vs. 40%). No serious adverse events were reported fol-
lowing vaccination.
Discussion. Oral Anticholeric vaccine proved to be effective and 
safe in preventing fecal-oral diseases in travelers exposed to high 
risk conditions.
The full article is free available on www.jpmh.org
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Introduction
Over the last few decades, globalisation has led to an 
increase in international travels to countries with poor 
hygiene standards, made for tourism, work or coopera-
tion and humanitarian projects. Fecal-orally transmitted 
diseases are an important health problem among people 
involved in these travels: their diffusion is strictly re-
lated to environmental fecalisation, limited availability 
of drinking water and, more generally, poor hygiene and 
sanitation level. Among the fecal-orally transmitted dis-
eases, the so-called traveler’s diarrhoea has a particu-
larly significant epidemiological impact and is identified 
as one of the most important diseases that occur during 
stay in developing countries [1-3]: according to differ-
ent studies [4-6], it causes up to 50% of the demands of 
health-care services. Traveler’s diarrhoea can be caused 
by different pathogens (bacteria, protozoa and viruses) 
and is characterised by diarrhoea of variable intensity 
and various enteric symptoms. In travelers up to 80% of 
diarrhoeal episodes are caused by bacteria, with Entero-
toxigenic Escherichia coli (ETEC) that is responsible 
for 30%-60% of all traveler’s diarrhoea cases, but also 
mild cholera infection can, even if rarely, cause it [7]. In 
microbiological terms, 140 serogroups of Vibrio chol-
erae are recognised on the basis of O somatic antigens, 
which are divided into ‘O1’ and ‘non-O1’ depending on 
their capacity to be agglutinated by group O1 antigen an-
tisera [8]. The O1 serogroup is divided into two biotypes 
(called Classic and El Tor) on the basis of characteristics 
such as phagic sensitivity and production of haemolysin, 
and each biotype is further divided into two serotypes: 
Ogawa and Inaba. Nowadays, only the O1 and O139 
Bengala serotypes are considered to be responsible for 
cholera epidemics  [9], whereas the vibrios of the oth-
er groups not producing cholera toxin only cause mild 
intestinal infections. Man is the only known host of V. 
cholerae. Although under-reported, cholera is still a ma-
jor public health problem and one of the key indicators 
of social development. Clinically, it ranges from mild or 
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moderate disease essentially characterised by diarrhoea 
with an evolution from benign to severe disease with a 
high mortality rate [10]. Because of its endemic/epidem-
ic nature, the disease is no longer a threat in countries 
with even minimal standards of hygiene, but remains a 
problem where it is not yet possible to guarantee every-
one access to potable water and adequate hygiene serv-
ices. With specific reference to travel medicine, the risk 
factors associated with the onset of traveler’s diarrhoea 
include: the country of origin (with people from indus-
trialised countries being at greater risk) [11], destination 
(high-risk areas are the Middle East, South and South-
east Asia, Central and South America, and developing 
countries in Africa)  [12] and particular clinical condi-
tions such as hypochlorhydria [8]. It is important to no-
tice that the ETEC’s pathogenic mechanism is similar to 
the V. cholerae’s one: both cause a secretory diarrhoea. 
ETEC produces a thermolabile (LT) and thermostable 
toxin (ST). LT is structurally closely related to and has 
the same effect as cholera enterotoxin and exerts its ef-
fect through the activation of adenylate cyclase [13]. The 
main epidemiological risk factor for the development of 
fecal-oral diseases is the exposure to contaminated wa-
ter or foodstuffs, or food prepared using contaminated 
water. Therefore, primary prevention seems to be fun-
damental for people visiting at-risk areas, and involves 
respecting the norms of correct personal and dietary 
hygiene, even if quite often there is no compliance to 
these rules. Moreover, an oral anti-cholera vaccine has 
recently become available, and it also protects against 
traveler’s diarrhoea (particularly ETEC-sustained) [14]. 
The aim of this study was to assess compliance with vac-
cination and incidence of “traveler’s diarrhoea” in sub-
jects vaccinated with oral vaccine Dukoral® and in un-
vaccinated ones, with regard to different variables such 
as travel’s duration, destination, motivation, subject’s 
age and gender.
Methods
Travel Medicine Centres of Ferrara, Agrigento, Reggio 
Calabria, Milan, Caserta, Paola, and Lucca participated 
in the study that involved patients of both genders who 
have travelled in areas at risk of cholera and traveler’s di-
arrhoea. Before the trip they were offered immunization 
with the oral anticholeric vaccine (Dukoral®), through 
an informative phase which took place at the travel med-
icine centres that participated in the study. Participants 
were asked to record any side effect appeared after tak-
ing the vaccine. At this time, participants received an 
informative brochure of the study. Upon returning, par-
ticipants completed a self-administered questionnaire, 
consisting of 40 close-ended questions mainly related 
to: personal and health data, characteristics of the travel 
(visited country, length and motivation), onset of gas-
trointestinal symptoms during the travel (length, inten-
sity and effects limiting normal activities), data relating 
to the assumption of anticholeric vaccine and possible 
adverse reactions. Taken drugs, and present or past ill-
nesses at the time of administration of the vaccine were 
taken into consideration. All data were collected accord-
ing to the actual standards related to the protection of 
privacy and in particular the Law Decree 196/2003, Ar-
ticle 24 (Code for the Protection of Personal Data) [15]. 
Completed questionnaires were collected by staff of par-
ticipating Centres. Data were stored through Excel 2003 
and processed by the statistical program SAS-JMP 7.0. 
The chi-squared test or, when required, chi-squared with 
yates’ correction or the Fisher exact test were applied, 
and the results were considered statistically significant if 
p < 0.05. Each dose of the offered vaccine contains a to-
tal of 1011 heat-inactivated cells of V. cholerae serotype 
Inaba and Ogawa classical and El Tor biotypes and the 
recombinant choleric toxin B subunit, and it induces the 
formation of secretory IgA directed against these com-
ponents. So, the vaccine helps the prevention of both the 
colonization of the gut epithelium by the Vibrio and the 
effect of the toxin. 
Given the structural correlation between the cholera 
toxin and the LT of ETEC, the vaccine also confers pro-
tection against the most common pathogenic cause of 
traveler’s diarrhoea through a mechanism of immuno-
logical cross-reaction [13]. The protocol of administra-
tion involved the use of two oral doses spaced at least a 
week, with the last one taken at least 7 days before the 
beginning of the travel.
Results
In the period 2008-2009, a total of 296 questionnaires 
were collected. For each analyzed variable the non-re-
spondents were excluded from processing. Mean age of 
the subjects was 38.2 years (SD 13.0), 51.4% of the sub-
jects were younger than 35 years old, males were 55.4% 
and females 44.6%. Mean journey length was 22.2 days 
(SD 20.3), the majority of the trips were made for tour-
ism (66.8%, mean 16.8 days, mean age 38.7 years) and 
the remaining for business or cooperation (mean dura-
tion 32.8 days, mean age 37.5 years). Africa, Asia, and 
Central-South America were the preferred destinations 
(respectively 48.1%, 32.1% and 17.8% of the travelers). 
After being informed of the characteristics of the antic-
holeric vaccine by the personnel of the travel medicine 
centres, a total of 199 subjects (67.2%, mean age 38.5 
yrs, 53% males, 47% females) were properly vaccinated 
with Dukoral® versus 97 who were not (32.8%, mean 
age 37.7 yrs, 60.4% males, 39.6% females). At the time 
of departure, 45 subjects were receiving drugs for con-
current pathologies: 42 of them were vaccinated, none 
of them was receiving drugs able to interfere with the 
onset of traveler’s diarrhoea or with the vaccine. The 
presence of traveler’s diarrhoea was evaluated with a 
specific question in the questionnaire. We considered as 
positive the subjects that reported three or more bursts 
of diarrhoea in a 24-hours period during their travel. 
According to this definition, diarrhoea affected 14.1% 
of vaccinated subjects versus 20.6% of unvaccinated 
ones. We focused attention on the variables: ‘length of 
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the journey’ (divided into <  15 days, 15-28 days, and 
>  28 days classes), ‘geographical area’ (Africa, Asia, 
Central-South America, Oceania, etc.), ‘reason of the 
journey’ (work and cooperation, or tourism). We also 
took into account the variables: ‘age’ (< 35, 35-49, > 49 
years), ‘gender’ and ‘intensity of diarrhoea’. Regarding 
the length of the trip (Tab. I), there was a significant dif-
ference in incidence of diarrhoea in travel longer than 
28 days (incidence of diarrhoea in vaccinated 12.1%; 
in unvaccinated 40.0%; p = 0.039, efficacy 69.7% and 
number needed to treat to prevent one case of travel-
ler’s diarrhoea is 3.6). In addition, in this kind of travel, 
the incidence of diarrhoea among vaccinated and unvac-
cinated subjects was different especially for those who 
have travelled to Central and South America (0% in 
vaccinated vs. 80.0% in non-vaccinated; and for those 
who travelled for purpose of work or cooperation (5% in 
vaccinated, 43.8% in unvaccinated; p = 0.0121). At the 
same time, however, the good result obtained by vac-
cination in these subjects is confirmed considering that, 
on average, travels in Central-South America last longer 
than in the rest of the world (27.0 vs. 21.2 days). Another 
considered variable was the age of the subjects (Tab. II). 
In this case, there has been a significant difference in the 
onset of diarrhoea among vaccinated and unvaccinated 
subjects in the < 35 years age class: the 13.7% of vac-
cinated presented diarrhoea, compared to the 27.1% of 
non-vaccinated ones (p = 0.0470), with an efficacy of 
vaccination equal to 49.3% and a number needed to treat 
to prevent one case of traveller’s diarrhoea of 7.5. In 
subjects between 35 and 49 years, diarrhoea hit 11.8% of 
vaccinated and 19.4% of non-vaccinated (p = 0.3457), 
whereas in the > 50 years age class it involved 19.1% 
and 5.6% of subjects, respectively (p = 0.2551), but in 
this late group the number of subjects was really low.
Taking into consideration the length of the trip, it is 
noteworthy that subjects under the age of 35 years have 
made longer journeys than those belonging to over 35 
age class (24.1 vs. 20.4 days, p  =  0.0122). Regarding 
the reason that led to undertake the journey (Tab.  III), 
and taking in consideration all age classes, it is to be 
noted that in work or cooperation-related journeys, the 
14.1% of vaccinated and the 35.0% of unvaccinated sub-
jects suffered diarrhoea (p = 0.0313). It demonstrated a 
vaccine efficacy equal to 59.7%. Moreover, considering 
only the age class < 35 years, there was a difference in 
the incidence of diarrhoea among vaccinated (16.2%) 
and unvaccinated (50.0%) subjects in relation to work 
or cooperation trips (p = 0.0252) compared to trips made 
for tourism. There was no significant gender-related dif-
ference in the incidence of diarrhoea, both in vaccinated 
(males 13.3%, females 15.5%; p = 0.7288) and in un-
vaccinated individuals (males 22.4%, females 18.4%, 
p = 0.6376).
Although the percentage of subjects who experienced di-
arrhoea have been consistently lower in vaccinated than 
unvaccinated subjects, there were no significant differ-
ences regarding the destination of the trip (Tab.  IV) 
(Central-South America: cases of diarrhoea in vaccinat-
ed 14.7%, in unvaccinated 38.9%, p = 0.0819; Africa: 
cases of diarrhoea in vaccinated 10.6%, in unvaccinated 
12.8%, p  =  0.7073; Asia: cases of diarrhoea in vacci-
nated 19.7%, in unvaccinated 21.4%, p = 0.8484). Fi-
nally, the onset of diarrhoea with a severe intensity was 
found more frequently in unvaccinated subjects (15.0% 
vs. 11.1%), whereas cases of mild intensity occurred 
more frequently in vaccinated ones (33.3% vs. 25%). 
Noteworthy, the vaccine was confirmed safe as serious 
adverse reactions have not been reported.
Discussion
Prevention of fecal-orally transmitted diseases is a pri-
ority for subjects who travel to high endemic areas. 
Among these diseases, traveler’s diarrhoea has a consid-
erable epidemiological impact because of the significant 
reduction of the regular activities during the journey [5]. 
Prevention of fecal-orally transmitted diseases requires 
the adoption of specific hygienic and behavioural stand-
ards: moreover, nowadays, it is possible to be vaccinated 
against some of them.
These behavioural rules are well summarized by saying 
“Cook it, peel it, boil it or forget it!”. In fact, the main 
risk factor for fecal-oral transmission is the ingestion of 
contaminated water or food: therefore, the main rules 
Tab. I. rate of diarrhoea in subjects not vaccinated and vaccinated, stratified by length of journey.
Length of journey Not vaccinated (%) Vaccinated (%) p
< 15 gg 21.6 12.3 0.2136
15-28 10.5 16.2 0.5896
> 28 40.0 12.1 0.0390
Tab. II. rate of diarrhoea in subjects not vaccinated and vaccinated, stratified by age class.
Age class Not vaccinated (%) Vaccinated (%) p
< 35 27.1 13.7 0.0470
35-49 19.4 11.8 0.3457
> 49 5.6 19.1 0.2551
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imply that a traveler should attend to the exclusive in-
gestion of bottled water, peeled fruit, and cooked food. 
Although well known, these rules are frequently disre-
garded, and especially young people undertake more 
so-called ‘adventurous’ trips during which they don’t 
want to, or actually cannot strictly adhere to those rules. 
These trips, in fact, often provide outdoor activities and 
a closer contact with nature and the population of the 
visited areas thus creating situations where it is difficult 
to avoid contact with contaminated water or food.
These observations could be the basis of the data shown in 
the present study where we found a significant difference 
in the onset of diarrhoea among vaccinated and unvac-
cinated subjects belonging to age group < 35 years, that 
represented the 51.4 % of the participants to this study. 
Moreover the younger people will, presumably, find 
themselves in situations at risk of fecal-oral disease trans-
mission for the style of travel they typically take. There-
fore, this age group experiences the greatest number of 
cases of traveler’s diarrhoea and it is consequently pos-
sible to verify more accurately the difference in the onset 
of the disease in subjects vaccinated with Dukoral® vs. 
unvaccinated ones, and the good efficacy of the vaccine.
The results of the present study are based on a relatively 
small sample, therefore they should be viewed with cau-
tion. The study was not randomized; we therefore can-
not exclude that those willing to be vaccinated might be 
more motivated to avoid diarrhoea risks. The question-
naire was compiled upon returning from the travel and 
a certain degree of recall bias may have occurred. How-
ever, a recent Spanish study  [16] is in line with these 
considerations: it analyzed the occurrence of traveler’s 
diarrhoea in vaccinated and unvaccinated subjects, 
considering a sample composed exclusively of young 
travelers (aged 18 to 30 years). It showed that 17.4% of 
young vaccinated travelers experienced at least one at-
tack of diarrhoea compared to 39.7% of non-vaccinated 
(p < 0.01) and also the length of the episode of diarrhoea 
in the first group was at least one day shorter compared 
to the other group. Risk exposure and reason of travel 
showed a likewise strict relationship in case of journeys 
aimed at cooperation. We may suppose that interna-
tional cooperation-related travels expose the subject to 
hardly controllable environmental and sanitary condi-
tions, and imply an increased length of stay in a foreign 
country, leading to prolonged exposure to risk factors 
for fecal-oral diseases. In this context the study showed 
the best results in terms of decline in the incidence of di-
arrhoea in vaccinated vs. unvaccinated subjects in long 
lasting journeys. Therefore, the efficacy of the vaccine 
emerges more clearly in these situations. Moreover, this 
study highlights how a vaccine against cholera (Duko-
ral®) proved effective in preventing traveler’s diarrhoea, 
too (it is anyway important to remember that the EMEA 
authorized Dukoral® to be sold within European Com-
munity as a vaccine against cholera only). The scien-
tific community suggests the advisability of extending 
the anticholeric vaccination to people living in areas of 
high endemicity or otherwise exposed to hygiene condi-
tions at high risk of transmission of fecal-oral diseases, 
as well as in those situations where public health emer-
gencies related to conflicts or natural disasters are ex-
isting [17, 18]. In addition, some studies have shown a 
favourable cost-benefit of vaccination with oral antic-
holeric vaccine for travelers going to areas at high risk 
of fecal-orally transmitted diseases, regardless of the 
length of the journey and the visited country. In fact, 
due to the very high incidence of traveler’s diarrhoea the 
number needed to treat to prevent one case is really low 
and in line with the results found by other authors [19].
Conclusions
Oral anticholeric vaccine (WC/rBS, Dukoral®) repre-
sents a good opportunity of prevention especially when 
travelers are confronted with conditions at higher risk of 
transmission of fecal-oral diseases (in relation to the geo-
graphical area they travel to, duration of the travel, ability 
to control environmental and sanitary conditions).
Tab. III. rate of diarrhoea in subjects not vaccinated and vaccinated, stratified by reason of travel.
Reason of travel Not vaccinated (%) Vaccinated (%) p
work/Cooperation 35.0 14.1 0.0313
Tourism 16.9 14.2 0.6046
Tab. IV. rate of diarrhoea in subjects not vaccinated and vaccinated, stratified by destination of journey.
Destination Not vaccinated (%) Vaccinated (%) p
africa 12.8 10.6 0.7073
asia 21.4 19.7 0.8484
Central/South america 38.9 14.7 0.0819
aNTICholerIC vaCCINe for TravelerS
203
References
[1] Steffen R. Epidemiologic studies of travelers’ diarrhoea, se-
vere gastrointestinal infections, and cholera. Rev Infect Dis 
1986;8(Suppl. 2):S122-30.
[2] Bruni M, Steffen R. Impact of travel-related health impair-
ments. J Travel Med 1997;4:61-4.
[3] Shlim DR. Update in traveler’s diarrhoea. Infect Dis Clin 
North Am 2005;19:137-49.
[4] Steffen R, Rickenbach M, Wilhelm U, et al. Health problems af-
ter travel to developing countries. J Infect Dis 1987;156:84-91.
[5] Al-Abri SS, Beeching NJ, Nye FL. Traveler’s diarrhoea. Lan-
cet Infect Dis 2005;5:349-60.
[6] Wiedermann U, Kollaritsch H. Vaccines against traveler’s 
diarrhoea and rotavirus disease a review. Wien Klin Wochen-
scher 2006;118:2-8.
[7] Black RE. Epidemiology of travelers’ diarrhoea and relative 
importance of various pathogens. Rev Infect Dis 1990;12(Sup-
pl. 1):S73-9.
[8] Jiang ZD, Lowe B, Verenkar MP, et al. Prevalence of enteric 
pathogens among international travelers with diarrhoea ac-
quired in Kenya (Mombasa), India (Goa), or Jamaica (Montego 
Bay). J Infect Dis 2002;185:497-502.
[9] Torrel JM, Aumatell CM, Ramos SM, et al. Reduction of travel-
ers’ diarrhoea by WC/rBS oral cholera vaccine in young, high-
risk travelers. Vaccine 2009;27:4074-7.
[10] Weinke T, Liebold I, Burchard GD, et al. Prophylactic immunization 
against traveler’s diarrhoea caused by enterotoxin-forming strains 
of Escherichia coli and against cholera: does it make sense and for 
whom? Travel Medicine and Infectious Disease 2008;6:362-7.
[11] Sack DA, Sack B, Balakrish Nair G, et al. Cholera. Lancet 
2004;363:223-33.
[12] WHO. Cholera.Fact sheet n.  107,2010. http://www.who.int/
mediacentre/factsheets/fs107/en/index.html
[13] JD Clements, Finkelstein RA. Demonstration of shared and 
unique immunological determinants in enterotoxins from Vibrio 
cholerae and Escherichia coli. Infect Immun 1978;22:09-713.
[14] Peltola H, Siitonen A, Kyrönseppä H, et al. Prevention of trav-
ellers’ diarrhoea by oral B-subunit/whole-cell cholera vaccine. 
Lancet 1991;338:1285-9.
[15] Sally J, Trippel MD, Arguin PM, et al. CDC Health Information 
for International Travel 2008. Chicago (IL): Mosby 2007.
[16] Ryan ET, Calderwood SB. Cholera vaccines. Clin Infect Dis 
2000;31:561-5.
[17] Codice in materia di protezione dei dati personali. D.lgs n. 
196/2003 published on GU n. 174 del 29-7- 2003. Suppl. Ordi-
nario n. 123.
[18] Clemens J, Holmgren J. Urgent need of cholera vaccines in pub-
lic health-control programs. Future Microbiol 2009;4:381-5.
[19] Chaignat CL. What about cholera vaccines? Expert Review of 
Vaccines 2008;7:403-5.
n	 Received on June 22, 2012. Accepted on September 7, 2012. 
n	 Correspondence: Giovanni Gabutti, Department of Prevention, 
O.U. Hygiene and Public Health, LHU 4 Chiavarese-Regione Li-
guria, Italy, corso Dante 163, 16043 Chiavari (GE) Italy - Tel. +39 
0185 329045 - Fax + 39 0185 324683 - E-mail: ggabutti@asl4.ligu-
ria.it
